echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Chuangsheng group announced the completion of $100 million B + round financing

    Chuangsheng group announced the completion of $100 million B + round financing

    • Last Update: 2020-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, we announced the successful completion of the US $100 million B + round of financing, which is jointly led by China Resources Zhengda life science fund and Dachen finance and intelligence Yipu capital, China Merchants capital national investment promotion and merger fund and SINOSURE as new investors participate in the follow-up investment The existing investors include China Lilly Asia Fund, Temasek, Hillhouse capital, Tengyue fund, Sequoia Capital China fund and arch venture Partners continue to participate Huaxing capital acted as the exclusive financial advisor for this transaction.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.